Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | Probable multifunctional mycocerosic acid synthase membrane associated enzyme Mas | 0.0659 | 0.4752 | 0.6337 |
Mycobacterium tuberculosis | Phenyloxazoline synthase MbtB (phenyloxazoline synthetase) | 0.058 | 0.3948 | 0.528 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSE | 0.041 | 0.2228 | 0.2941 |
Mycobacterium ulcerans | multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks5 | 0.0602 | 0.4168 | 0.5576 |
Mycobacterium tuberculosis | Polyketide synthase Pks12 | 0.0659 | 0.4752 | 0.6357 |
Toxoplasma gondii | beta-ketoacyl synthase, N-terminal domain-containing protein | 0.0403 | 0.2149 | 0.2574 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0659 | 0.4752 | 0.6357 |
Onchocerca volvulus | 0.108 | 0.9025 | 0.9285 | |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0659 | 0.4752 | 1 |
Mycobacterium ulcerans | polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium ulcerans | polyketide synthase Pks9 | 0.041 | 0.2228 | 0.2981 |
Mycobacterium tuberculosis | Polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks1 | 0.0446 | 0.2588 | 0.3461 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks9 | 0.0353 | 0.1644 | 0.2199 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.058 | 0.3948 | 0.3889 |
Mycobacterium tuberculosis | Polyketide synthetase MbtC (polyketide synthase) | 0.0213 | 0.0229 | 0.0306 |
Brugia malayi | Beta-ketoacyl synthase, N-terminal domain containing protein | 0.0621 | 0.4361 | 0.4361 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsB | 0.0499 | 0.3131 | 0.4188 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Probable fatty acid synthase Fas (fatty acid synthetase) | 0.0195 | 0.0042 | 0.0056 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium leprae | Polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0499 | 0.3131 | 0.4188 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSD | 0.0621 | 0.4361 | 0.581 |
Mycobacterium tuberculosis | Probable multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium leprae | PROBABLE THIOESTERASE TESA | 0.0517 | 0.3311 | 0.4398 |
Onchocerca volvulus | Fatty acid synthase homolog | 0.1119 | 0.9416 | 1 |
Mycobacterium ulcerans | fatty acid synthase Fas | 0.0195 | 0.0042 | 0.0056 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks15 | 0.0251 | 0.061 | 0.0817 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | thioesterase | 0.0517 | 0.3311 | 0.443 |
Loa Loa (eye worm) | hypothetical protein | 0.1043 | 0.8643 | 1 |
Mycobacterium leprae | Probable polyketide synthase Pks1 | 0.0659 | 0.4752 | 0.6337 |
Mycobacterium tuberculosis | Probable thioesterase TesA | 0.0517 | 0.3311 | 0.443 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsE | 0.041 | 0.2228 | 0.2981 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks8 | 0.0508 | 0.3214 | 0.4299 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC | 0.0659 | 0.4752 | 0.6337 |
Schistosoma mansoni | serine-type protease inhibitor | 0.0532 | 0.3462 | 0.5 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks7 | 0.0659 | 0.4752 | 0.6357 |
Loa Loa (eye worm) | hypothetical protein | 0.0348 | 0.1592 | 0.0823 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0442 | 0.2547 | 0.3708 |
Loa Loa (eye worm) | fatty acid synthase | 0.0612 | 0.4277 | 0.4318 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA | 0.0621 | 0.4361 | 0.581 |
Schistosoma mansoni | serine-type protease inhibitor | 0.0532 | 0.3462 | 0.5 |
Mycobacterium tuberculosis | Probable membrane bound polyketide synthase Pks6 | 0.0928 | 0.7476 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.058 | 0.3948 | 0.3948 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB | 0.0499 | 0.3131 | 0.4155 |
Mycobacterium ulcerans | polyketide synthase | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium tuberculosis | Polyketide synthase Pks2 | 0.0602 | 0.4168 | 0.5576 |
Mycobacterium ulcerans | thioesterase TesA | 0.0517 | 0.3311 | 0.443 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 2.7 uM | Inhibition of [3H]-thymidine incorporation into the DNA of uninfected HeLa cells | ChEMBL. | 7752206 |
IC50 (functional) | = 3.4 uM | Inhibition against DNA of uninfected HEL cells by incorporation of [3H]-TdR. | ChEMBL. | 7752205 |
IC50 (functional) | = 7.9 uM | Inhibition of human CMV DNA synthesis in CMV-infected HEL cells. | ChEMBL. | 7752205 |
IC50 (functional) | = 23 uM | Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells | ChEMBL. | 7752206 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.